| Expression pattern: |
DN |
| Associated gene: |
HuR (ELAVL1), beta-Trcp1, PTBP1, FUS, ADARB2 |
| Associated microRNA: |
- |
| Biological function: |
Suppresses colorectal cancer cell migration and invasion and inhibits metastasis (including lung metastasis) with little/no effect on proliferation or apoptosis; modulates EMT marker expression. |
| Molecular mechanism: |
circRHOBTB3 binds the RBP HuR and promotes beta-Trcp1-mediated ubiquitination and proteasomal degradation of HuR, thereby decreasing HuR-dependent PTBP1 mRNA stability and PTBP1 expression; FUS and ADARB2 promote circRHOBTB3 biogenesis by binding flanking intronic motifs/Alu elements. |
| Biological pathway or process: |
metastasis (inhibits); migration (inhibits); invasion (inhibits); EMT (inhibits); mRNA stability (inhibits); ubiquitination (promotes); glycolysis (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Back-Splice Junction PCR / divergent primers PCR; FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); Transfection; CCK8; Transwell Assay; Wound Healing Assay; Western Blot; Co-IP; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Bioinformatics Analysis; ROC Analysis |
| Clinical significance: |
Lower circRHOBTB3 levels were significantly associated with advanced clinical stages and greater risk of metastases; ROC analysis indicated diagnostic potential for advanced-stage CRC. |
| Description: |
circRHOBTB3 is down-regulated in colorectal cancer and functions as a metastasis suppressor. It binds HuR and promotes beta-Trcp1-mediated ubiquitination/proteasomal degradation of HuR, reducing HuR-stabilized PTBP1 mRNA and thereby inhibiting EMT-associated migration/invasion and lung metastasis. |
| Confidence score: |
0.8747 |